| 杨友卫,李玲玲,李萨萨,侯小芳,许 力.国产利妥昔单抗治疗弥漫大B细胞淋巴瘤的疗效及安全性[J].现代生物医学进展英文版,2023,(13):2533-2536. |
| 国产利妥昔单抗治疗弥漫大B细胞淋巴瘤的疗效及安全性 |
| To Evaluate the Efficacy and Safety of Domestic Rituximab in the Treatment of DLBCL |
| Received:December 31, 2022 Revised:January 27, 2023 |
| DOI：10.13241/j.cnki.pmb.2023.13.026 |
| 中文关键词: 国产利妥昔单抗 弥漫大B细胞淋巴瘤 生物类似药 不良反应 |
| 英文关键词: Domestic rituximab Diffuse large B-cell lymphoma Biosimilar drugs Adverse reactions |
| 基金项目:安徽省高校自然科学研究重点项目（KJ2019A1105） |
|
| Hits: 512 |
| Download times: 357 |
| 中文摘要: |
| 摘要 目的：探讨弥漫大B细胞淋巴瘤患者采用国产利妥昔单抗为基础的化疗方案的疗效及安全性。方法：回顾性分析2020年3月至2022年5月份在安徽省第二人民医院血液内科诊治的弥漫大B淋巴瘤患者31例，均接受国产利妥昔单抗为基础的联合方案化疗，其中非生发中心来源的弥漫大B细胞淋巴瘤患者25例，生发中心来源的弥漫大B细胞淋巴瘤患者6例。21~28 d为一个疗程，这些患者至少接受2~8个疗程的联合化疗，并且2个疗程以后进行疗效评估及不良反应监测。结果：①本研究31例弥漫大B细胞淋巴瘤患者接受利妥昔单抗为基础的联合化疗方案治疗后，疗效评估为完全缓解CR 16例（51.6%），部分缓解PR 10例（32.3%），疾病稳定SD 2例（6.5%），疾病进展PD 3例（9.7%），总体反应率ORR 83.9%。②31例弥漫大B细胞淋巴瘤患者接受国产利妥昔单抗治疗后，常见的不良反应发生率依次为：血液学毒性29.0%（9/31），包括中性粒细胞减少、血小板减少等等。其次为感染19.4%（6/31）、消化道症状16.1%（5/31），包括腹痛、腹泻、便秘等等。所有常见不良反应经过对症处理后均可好转。仅有1例患者发生过敏反应3.2%（1/31），1例患者因病情严重而死亡。结论：国产利妥昔单抗在弥漫大B细胞淋巴瘤患者的治疗中具有良好的临床疗效及安全性，不良反应较少，值得进一步探讨和应用。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the efficacy and safety of domestic rituximab-based chemotherapy in patients with diffuse large B-cell lymphoma. Methods: A total of 31 patients with diffuse large B cell lymphoma diagnosed in the Department of Hematology of Anhui No2 Provincial People's Hospital from March 2020 to May 2022 were retrospectively analyzed. All patients received domestic rituximab-based chemotherapy, including 25 patients with non-germinal center diffuse large B cell lymphoma and 6 patients with germinal center diffuse large B cell lymphoma.These patients received at least 2-8 cycles of combination chemotherapy for 21-28 days as a cycle, and the efficacy was evaluated and adverse events were monitored after 2 cycles. Results: In this study, 31 patients with diffuse large B-cell lymphoma were treated with rituximab-based combined chemotherapy, and the efficacy was evaluated as complete remission (CR) in 16 cases (51.6%), partial remission (PR) in 10 cases (32.3%), stable disease (SD) in 2 cases (6.5%), progressive disease (PD) in 3 cases(9.7%). The overall response rate was 83.9%. Among 31 patients with diffuse large B-cell lymphoma treated with domestic rituximab, the incidence of common adverse reactions was as follows: hematologic toxicity 29.0%(9/31), including neutropenia, thrombocytopenia, etc. Followed by infection 19.4% (6/31), gastrointestinal symptoms 16.1% (5/31), including abdominal pain, diarrhea, constipation and so on. All the common adverse reactions were improved after symptomatic treatment. Only 1 patient had anaphylaxis (3.2%, 1/31), and 1 patient died due to severe illness. Conclusion: Domestic rituximab has good clinical efficacy and safety in the treatment of patients with diffuse large B-cell lymphoma, with few adverse reactions, which is worthy of further exploration and application. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
